MRCP Recall Free flashcardsSign up free

New: our faculty are still reviewing these cards. Spotted an error? Use “Report an issue” on the card in the app, or contact us.

Cancer drugs: mechanism & toxicity flashcards

8 high-yield MRCP Part 1 cards from the Intellect Medicos Haematology & Oncology course. Try to answer each question before you open it — then study them properly with spaced repetition, which brings each card back just before you would forget it.

Study these 8 cards Save progress — free account

  1. What is the mechanism of methotrexate, and what is the antidote in toxicity?

    Show answer

    Dihydrofolate reductase inhibitor; folinic acid (calcium folinate) rescue.

    Why? Blocking DHFR depletes the tetrahydrofolate needed for DNA synthesis; folinic acid bypasses the block.

  2. Name three major toxicities of cisplatin.

    Show answer

    Any three of: nephrotoxicity, ototoxicity, peripheral neuropathy, hypomagnesaemia, severe nausea and vomiting.

    Why? Platinum compounds cross-link DNA; they accumulate in the kidney, inner ear and nerves.

  3. Before starting 5-fluorouracil or capecitabine, which enzyme deficiency must be tested for?

    Show answer

    Dihydropyrimidine dehydrogenase (DPD) deficiency.

    Why? DPD breaks down fluoropyrimidines; deficient patients can get severe or fatal toxicity (mucositis, diarrhoea, neutropenia).

  4. Trastuzumab targets which receptor, and what is its key toxicity?

    Show answer

    HER2; cardiotoxicity (fall in LVEF / heart failure) — monitor LVEF.

    Why? It is used in HER2-positive breast and gastric cancer. Unlike anthracycline damage, the cardiac dysfunction is usually reversible on stopping.

  5. What is the first-line treatment of a significant immune-related adverse effect (e.g. colitis or pneumonitis) from a checkpoint inhibitor such as pembrolizumab?

    Show answer

    Withhold the drug and give high-dose corticosteroids.

    Why? PD-1/PD-L1 and CTLA-4 inhibitors release the brakes on T cells, which can then attack normal tissues.

  6. Which two serious risks are increased by tamoxifen?

    Show answer

    Endometrial cancer and venous thromboembolism.

    Why? Tamoxifen is a selective oestrogen receptor modulator: an antagonist in the breast but a partial agonist in the endometrium and liver.

  7. What is the mechanism of action of hydroxycarbamide (hydroxyurea)?

    Show answer

    It inhibits ribonucleotide reductase, blocking DNA synthesis.

    Why? It is used for cytoreduction in PV, ET and CML and to raise HbF in sickle cell disease.

  8. A patient taking azathioprine is started on allopurinol for tumour lysis prophylaxis. What is the risk?

    Show answer

    Severe azathioprine (6-mercaptopurine) toxicity with bone marrow suppression — avoid the combination or cut the azathioprine dose to a quarter.

    Why? Allopurinol inhibits xanthine oxidase, which normally inactivates 6-mercaptopurine.

More Haematology & Oncology topics